Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medivir AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 374.13.
Medivir AB's Days Inventory for the
three
months ended in Mar. 2026 was 0.
Medivir AB's Days Payable for the
three
months ended in Mar. 2026 was 0.
Therefore, Medivir AB's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 374.13.
Medivir AB (OSTO:MVIR) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Medivir AB Cash Conversion Cycle Related Terms
Medivir AB Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Medivir AB's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MVIR vs VRTX, REGN, RVMD: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Medivir AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Medivir AB's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Medivir AB's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (OSTO:MVIR) has a Cash Conversion Cycle of 374.13 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medivir AB and its competitors.
Is Medivir AB's Cash Conversion Cycle too high?
Medivir AB's current Cash Conversion Cycle is 374.13. The Biotechnology industry median Cash Conversion Cycle is 103.69. Medivir AB's value of 374.13 is 260.8% above this industry median. Overall, Medivir AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Cash Conversion Cycle compare to VRTX and REGN?
Medivir AB's Cash Conversion Cycle of 374.13 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.69. Medivir AB's value of 374.13 is 260.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.69, based on 869 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medivir AB's current Cash Conversion Cycle of 374.13 is 260.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medivir AB and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current Cash Conversion Cycle is 374.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.80 — trading 62.2% above its estimated fair value. The current Cash Conversion Cycle is 374.13 and 260.8% above the Biotechnology industry median of 103.69. Medivir AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current Cash Conversion Cycle is 374.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (OSTO:MVIR) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.80 is trading 62.2% above its estimated GF Value™ of kr1.11.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for OSTO:MVIR:
Cash Conversion Cycle: 374.13
GF Value™: kr1.11 vs. price of kr1.80 (62.2% above fair value)
Industry Position: 260.8% above the Biotechnology median
No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score
Get the complete analysis for OSTO:MVIR
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MVIR has been successfully added to your 
